Status:
COMPLETED
Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia?
Lead Sponsor:
Birte Glenthoj
Collaborating Sponsors:
University of Copenhagen
Lundbeck Foundation
Conditions:
Schizophrenia
Eligibility:
MALE
18-45 years
Phase:
NA
Brief Summary
The investigators want to try to improve information processing in schizophrenic patients via pharmacological intervention. The hypothesis is that decreased noradrenergic activity will normalize infor...
Detailed Description
A number of reports in literature provide evidence for, among others, an increased central noradrenergic activity in schizophrenia. In addition to this increased noradrenergic activity, patients with ...
Eligibility Criteria
Inclusion
- Patients:
- Male subjects
- Meeting the DSM-IV diagnosis of schizophrenia
- Controls:
- Male subjects
- Good Physical and Mental Health meeting criteria "never mentally ill", which will be evaluated with a medical history checklist
- Non smokers
Exclusion
- Patients:
- A P50 suppression or PPI score falling within a range of 10 percent above or below the mean score of the healthy control group
- Controls:
- Current use of any medication
- Any subject who has received any investigational medication within 30 days prior to the start of this study
- History of neurologic illness
- History of psychiatric illness in first-degree relatives, evaluated with DSM-IV criteria
- History of alcohol and drug abuse.
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2011
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00206986
Start Date
May 1 2005
End Date
December 1 2011
Last Update
December 20 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup
Copenhagen NV, Denmark, DK-2400